Understanding Hepatitis B: Key Facts and Information

Key Facts

Hepatitis B is not just a medical term; it’s a viral infection that specifically targets the liver, leading to both acute (temporary) and chronic (long-term) health challenges. Here are some crucial facts about this significant global health concern:

• Nature of Infection: Hepatitis B is caused by the hepatitis B virus (HBV), capable of causing both acute and chronic infection.

• Transmission Routes: The virus primarily spreads from mother to child during birth, but it can also be transmitted through sexual contact, unsafe injections, and exposure to infected blood or body fluids.

• Global Prevalence: According to the World Health Organization (WHO), around 254 million people were living with chronic hepatitis B in 2022, with approximately 1.2 million new infections reported annually.

• Mortality Rates: Hepatitis B is deadly; it caused about 1.1 million deaths in 2022, mainly from cirrhosis and liver cancer.

• Vaccination: Fortunately, hepatitis B is preventable through safe and effective vaccinations, which can nearly eliminate the risk of infection.

Overview

Hepatitis B is a liver infection induced by the hepatitis B virus, which can manifest as either an acute or chronic condition. While acute infections tend to resolve on their own, chronic infections can lead to severe complications like cirrhosis (liver scarring) and hepatocellular carcinoma (liver cancer).

The virus spreads through contact with infected bodily fluids such as blood, saliva, and sexual fluids, and it’s also transmissible from an infected mother to her child during childbirth. Vaccination against hepatitis B is both effective and crucial, significantly reducing the overall incidence of the virus worldwide.

Global Impact

The burden of chronic hepatitis B infection is most severe in the WHO Western Pacific and African regions. In 2022, it was estimated that 97 million people were chronically infected in the Western Pacific region while 65 million faced similar issues in Africa. Other affected regions include Southeast Asia, Eastern Mediterranean, Europe, and the Americas.

Transmission

Understanding how hepatitis B is transmitted is essential for prevention. In areas with high rates of infection, the most common routes of transmission include:

• Perinatal Transmission: The virus is often passed from mother to child during childbirth.
• Horizontal Transmission: Infected children can transmit the virus to uninfected peers, especially in communal settings.

Other Transmission Methods

Beyond mother-to-child transfer and childhood transmission, hepatitis B also spreads via:

• Needlestick Injuries: In healthcare settings or through shared needles.
• Sexual Contact: Particularly among unvaccinated individuals with multiple partners.
• Exposure to Infected Body Fluids: This includes saliva, menstrual blood, and vaginal fluids.

Remarkably, the virus can survive outside the body for at least seven days, posing ongoing risks even after exposure. The incubation period for HBV can vary, but symptoms may appear within 30 to 180 days following exposure.

Symptoms

The silent nature of hepatitis B can be a double-edged sword. While many people don’t exhibit symptoms upon initial infection, some may experience acute illness manifesting in various ways:

• Jaundice: Yellowing of the skin and eyes.
• Dark Urine: A sign of liver distress.
• Fatigue: An overwhelming feeling of tiredness.
• Nausea and Vomiting: Common symptoms of liver problems.
• Abdominal Pain: Especially in the upper right area where the liver is located.

In more severe cases, acute hepatitis can lead to liver failure and even death. Even if someone recovers from an acute infection, those who develop chronic hepatitis B face a high risk of severe liver complications over time.

HBV-HIV Coinfection

Coinfection with HIV and HBV presents additional challenges for public health. Around 1% of individuals with HBV are also infected with HIV (approximately 2.7 million people). Conversely, about 7.4% of those living with HIV are also infected with HBV.

Since 2015, WHO has proposed that all HIV patients should receive treatment, with specific antiviral medications, such as Tenofovir, that are effective against HBV.

Diagnosis

Diagnosing hepatitis B requires laboratory confirmation, as symptoms alone are insufficient to distinguish it from other viral infections. Several blood tests can determine the presence of the HBV and assess the severity of liver disease.

WHO recommends testing all blood donations for hepatitis B to safeguard blood supplies and prevent unintended transmission. Alarmingly, as of 2022, only 13% of those who should be aware of their hepatitis B infection actually are, highlighting a significant gap in awareness and treatment.

Treatment

For acute hepatitis B, there is no specific treatment; instead, care focuses on symptom management and supportive measures. Individuals experiencing severe symptoms may require hospitalization and close medical supervision.

Chronic hepatitis B can be managed with antiviral medications, such as tenofovir and entecavir. These treatments aim to:

• Slow Disease Progression: Preventing cirrhosis development.
• Reduce Liver Cancer Risk: Minimizing long-term complications.
• Improve Survival Rates: Enhancing quality of life and life expectancy.

Lifelong treatment is often necessary for chronic patients, particularly those in lower-income settings where late presentation leads to higher mortality rates.

Prevention

The good news is that hepatitis B is preventable through vaccination. Infants should receive the vaccine within 24 hours of birth, followed by subsequent doses spaced appropriately. Importantly, booster shots are typically not needed for individuals who have completed the vaccination series.

To minimize the risk of infection, people are encouraged to:

• Practice Safe Sex: Use condoms to reduce transmission likelihood.
• Avoid Sharing Needles: Particularly in drug use or tattooing situations.
• Wash Hands Thoroughly: Especially after exposure to potential contaminants.

WHO Response

The WHO has developed global health sector strategies aimed at curtailing the spread of hepatitis B by 2030. These strategies emphasize prevention, testing, and treatment tailored to the needs of affected populations.

WHO organizes annual campaigns, such as World Hepatitis Day, to raise awareness about hepatitis infections while supporting countries in implementing effective public health responses. Through research and updated guidelines, the organization continually aims to reflect the latest science in its approach to combat hepatitis B effectively.